How Low Do You Need to Go? Association Between Various Prostate-Specific Antigen (PSA) Response Measures and Clinical Outcomes in Metastatic Castration‑Sensitive Prostate Cancer (mCSPC) in the Veterans Health Administration (VHA) Data
Freedland SJ, Gao W, Touya M, Yang H, Russell D, Chen J, Chen G, Ivanova JI
ASCO 2025
- 美国临床肿瘤学会年会 2025
| 肿瘤 | 前列腺癌 | 泌尿系统肿瘤
Final Patient-Reported Outcomes in Men W/ Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations Receiving Initial Treatment W/ Talazoparib Plus Enzalutamide vs Placebo Plus Enzalutamide in the TALAPRO-2 Study
Fay AP, Fizazi K, Matsubara N, Azad AA, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cislo P, Healy CG, Kirker M, Agarwal N
ASCO 2025
- 美国临床肿瘤学会年会 2025
| 肿瘤 | 前列腺癌 | 泌尿系统肿瘤 | 泰泽纳
Impact of Lorlatinib Dose Modifications on Adverse Event Outcomes in the Phase 3 CROWN Study
Liu G, Nadal E, Baijal S, Bulotta A, Baik CS, Thurm HC, Polli A, Nishio M,
ASCO 2025
- 美国临床肿瘤学会年会 2025
| 肿瘤 | 非小细胞肺癌 | 肺癌 | 博瑞纳
Depth of Response and Progression-Free Survival in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer Treated With Lorlatinib
Campelo RG, Schulz C, Min YJ, Aydiner A, Hussein M, DiPietro A, Polli A, Martini J-F, Kim HR
ASCO 2025
- 美国临床肿瘤学会年会 2025
| 肿瘤 | 非小细胞肺癌 | 肺癌 | 博瑞纳
